Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-01-31
2008-10-14
Minnifield, N. M (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S184100, C424S234100, C424S246100, C530S350000, C514S002600
Reexamination Certificate
active
07435418
ABSTRACT:
The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the polynucleotides and polypeptides, host cells containing related polynucleotide molecules, and cells displaying no anthrax toxin receptor on an exterior surface of the cells—minus cell lines and animals. The present invention also relates to methods for identifying molecules that bind the anthrax toxin receptor and molecules that reduce the toxicity of anthrax toxin. Finally, the present invention provides methods for treating human and non-human animals suffering from anthrax.
REFERENCES:
patent: 5591631 (1997-01-01), Leppla et al.
patent: 5677274 (1997-10-01), Leppla et al.
patent: 6022855 (2000-02-01), Thomas et al.
patent: 6329156 (2001-12-01), Cirino et al.
patent: 6485925 (2002-11-01), Duesbery et al.
patent: 6569662 (2003-05-01), Tang et al.
patent: 6592872 (2003-07-01), Klimpel et al.
patent: 7074913 (2006-07-01), Young et al.
patent: 7365184 (2008-04-01), Jones et al.
patent: 2002/0039588 (2002-04-01), Collier et al.
patent: 2002/0048590 (2002-04-01), Klimpel et al.
patent: 2002/0051791 (2002-05-01), Galloway et al.
patent: 2002/0142002 (2002-10-01), Galloway et al.
patent: 2002/0197272 (2002-12-01), Galloway et al.
patent: 2003/0003109 (2003-01-01), Galloway et al.
patent: 2003/0017157 (2003-01-01), St. Croix et al.
patent: 2003/0096333 (2003-05-01), Duesbery et al.
patent: 2003/0108556 (2003-06-01), Mekalanos et al.
patent: 2003/0119720 (2003-06-01), Khan et al.
patent: 2003/0198651 (2003-10-01), Klimpel et al.
patent: 2003/0202989 (2003-10-01), Collier et al.
patent: 2004/0010134 (2004-01-01), Rosen et al.
patent: 2005/0196407 (2005-09-01), Young et al.
patent: 2005/0287149 (2005-12-01), Keler et al.
patent: 2006/0083746 (2006-04-01), Young et al.
patent: 2006/0084794 (2006-04-01), Rosen et al.
patent: 2006/0110801 (2006-05-01), Young et al.
patent: 2006/0204525 (2006-09-01), Rest et al.
patent: 2006/0258842 (2006-11-01), Groen et al.
patent: 2007/0037206 (2007-02-01), Rosen et al.
patent: 2007/0041963 (2007-02-01), Rosen et al.
patent: 2007/0117159 (2007-05-01), Young et al.
patent: 2007/0118934 (2007-05-01), Yu et al.
patent: WO 00/39284 (2000-07-01), None
patent: WO 00/39284 (2000-07-01), None
patent: WO 01/34626 (2001-05-01), None
patent: WO 01/53312 (2001-07-01), None
patent: WO 01/53312 (2001-07-01), None
patent: WO 01/77137 (2001-10-01), None
patent: WO 02/10217 (2002-02-01), None
patent: WO 02/46228 (2002-06-01), None
Rigden et al, Trends in Biochemical Sciences, Jul. 2004, 29/7:335-339.
Suzuki et al, Gene, 1997, 200:149-156.
Liu et al, Expert Opin. Biol. Ther., 2003, 3/5:843-853.
Scobie et al, Current Opinion in Microbiology, 2005, 8:106-112.
Cunningham et al, PNAS, May 14, 2002, 99/10:7049-7053.
Bhatnagar et al, Critical Reviews in Microbiology, Sep. 2001, 27/3:167-200 abstract only.
Scobie, Dissertation Abstracts International, 2006, 67/6B:2956 abstract only.
Collier et al, Annu. Rev. Cell Dev. Biol., 2003, 19:45-70.
Batra, et al., BBRC 281:186-192 (2001).
Beauregard, et al., “Anthrax Toxin Entry into Polarized Epithelial Cells,” Infection and Immunity 67:3026-3030 (1999).
Benson, et al., Biochemistry 37:3941-48. (1998).
Boerger, et al., “Retroviral vectors preloaded with a viral receptor-ligand bridge protein are targeted to specific cell types,” Proc. Natl. Acad. Sci. USA 96:9867-9872 (1999).
Bradley, et al., Nature, 414:225-228, Nov. 8, 2001.
Chauhan, et al., Infection and Immunity 70/8:4477-84 (2002).
Cunningham, et al., PNAS 99/10:7049-53 (2002).
Dickeson, et al., “Ligand recognition by the I domain-containing integrins,” CMLS, Cell. Mol. Life Sci. 54:556-566 (1998).
Elliott, et al., Biochemistry, 39:6706-6713 (2000).
Elliott, Jennifer, “Assembly and Translocation of Anthrax Toxin,” Ph.D. Thesis, Department of Microbiology (Cambridge, MA, Harvard University) pp. 35-65 (1998).
Escuyer, et al., “Anthrax Protective Antigen Interacts with a Specific Receptor on the Surface of CHO-K1 Cells,” Infection and Immunity 59:3381-3386 (1991).
Genbank Accession No. AAD05303 (2001).
Genbank Accession No. AF279145 (2001).
Genbank Accession No. AF421380 (2001).
Genbank Accession No. AK001463, “Homo sapienscDNA FLJ10601 fis, clone NT2RP2005000,” NCB1 Sequence Viewer 2 pages (Sep. 28, 2001).
Genbank Accession No. BC012074, “Homo sapiens, similar to tumor endothelial marker 8, clone MGC:19967 Image:4563020, mRNA, complete cds,” NCB1 Sequence Viewer 2 pages (Sep. 25, 2001).
Genbank Accession No. NM—032208, “Homo sapienstumor endothelial marker 8 (TEM8), mRNA,” NCB1 Sequence Viewer 3 pages (Nov. 2, 2001).
Gordon, et al., “Inhibitors of Receptor-Mediated Endocytosis Block the Entry ofBacillus anthracisAdenylate Cyclase Toxin but Not That ofBordetella pertussisAdenylate Cyclase Toxin” Infection and Immunity 56:1066-1069 (1988).
Hanna, et al., “On the role of macrophages in anthrax,” Proc. Natl. Acad. Sci. USA 90:10198-10201 (1993).
Hanna, P., “Anthrax Pathogenesis and Host Response,” Current Topics in Microbiology and Immunology 225:13-35 (1998).
Holtzman, D.A., “Human Tango 197 Coding Sequence,” EMBL Accession #AAA47455 (2000).
Holtzman, D.A., “Human Tango 198,” EMBL Accession #AAB01422 (2000).
Klimpel, et al., “Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin,” Proc. Natl. Acad. Sci. USA 89:10277-10281 (1992).
Kumar, et al., Infection and Immunity 69/10:6532-36 (2001).
Lee, et al., “Crystal Structure of the A Domain from the Subunit of Integrin CR3 (CD11b/CD18),” Cell 80:631-638 (1995).
Leppla, et al. “ISolation and Characterization of Chinese Hamster Ovary Cell Mutants Lacking the Receptor for Anthrax Toxin Protective Antigen,” Bacterial protein Toxins, Zbl. Bakt. Suppl. 28 (1996).
Leppla, Stephan A., “The bifactorialBacillus anthracislethal and oedema toxins,” The Comprehensive Sourcebook of Bacterial Protein Toxins Chapter 12:243-263 (1999).
Menard, et al., “The vacuolar ATPase proton pump is required for the cytotoxicity ofBacillus anthracislethal toxin,” FEBS Letters 386:161-164 (1996).
Miller, et al., “Anthrax Protective Antigen: Prepare-to-Pore Conversion,” Biochemistry 38:10432-10441 (1999).
Milne, et al., Mol. Microbiol. 15/4:661-666 (1995).
Milner, et al., “Anthrax Protective Antigen Forms Oligomers during Intoxication of Mammalian Cells,” The Journal of Biological Chemistry 269:20607-20612 (1994).
Mogridge, et al., J. Bacteriology 183/6:2111-116 (2001).
Mourez, et al., Trends in Microbiology, 10/6:287-93 (2002).
Pannifer, et al., Nature, 414:229-233, Nov. 8, 2001.
Petosa, et al., “Crystal structure of the anthrax toxin protective antigen,” Letters to Nature 385:833-838 (1997).
Rosen, et al., “Human Albumin Fusion Protein #549,” EMBL Accession #ABG63874 (2002).
Ruben, et al., “Human Gene 4 Encoded Secreted Protein HWLFR02, SEQ ID No. 94,” EMBL Accession #AAE01439 (2001).
Ruben, et al., “Human Secreted Protein-Encoding Gene 4 cDNA Clone HWLFR02, SEQ ID No. 14,” EMBL Accession #AAD05303 (2001).
Snitkovsky, et al, “Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein,” Proc. Natl. Acad. Sci. USA 96:7063-7068 (1998).
Snitkovsky, et al, “Targeting Avian Leukosis Virus Subgroup A Vectors by Using a TVA-VEGF Bridge Protein,” Journal of Virology 75:1571-1575 (2001).
Snitkovsky, et al., “A TVA-Single-Chain Antibody Fusion Protein Mediates Specific Targeting of a Subgroup A Avian Leukosis Virus Vector to Cells Expressing a Tumor-Specific Form of Epidermal Growth Factor Receptor,” Journal of Virology 74:9540-9545 (2000).
St. Croix, et al., “Human Tumour Endothelial Mar
Bradley Kenneth A
Collier R. John
Mogridge Jeremy S.
Young John A. T.
Minnifield N. M
President and Fellows of Harvard College
Quarles & Brady LLP
Wisconsin Alumni Research Foundation
LandOfFree
Receptor for B. anthracis toxin does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Receptor for B. anthracis toxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Receptor for B. anthracis toxin will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4018732